KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Issued
Ratios

Edwards Lifesciences (EW) Accumulated Depreciation & Amortization (2016 - 2025)

Edwards Lifesciences has reported Accumulated Depreciation & Amortization over the past 14 years, most recently at $156.6 million for Q4 2025.

  • Quarterly results put Accumulated Depreciation & Amortization at $156.6 million for Q4 2025, up 0.9% from a year ago — trailing twelve months through Dec 2025 was $156.6 million (up 0.9% YoY), and the annual figure for FY2025 was $156.6 million, up 0.9%.
  • Accumulated Depreciation & Amortization for Q4 2025 was $156.6 million at Edwards Lifesciences, up from $155.2 million in the prior quarter.
  • Over the last five years, Accumulated Depreciation & Amortization for EW hit a ceiling of $156.6 million in Q4 2025 and a floor of $139.6 million in Q4 2022.
  • Median Accumulated Depreciation & Amortization over the past 4 years was $150.0 million (2023), compared with a mean of $149.1 million.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: increased 7.11% in 2024 and later increased 0.9% in 2025.
  • Edwards Lifesciences' Accumulated Depreciation & Amortization stood at $139.6 million in 2022, then grew by 3.8% to $144.9 million in 2023, then increased by 7.11% to $155.2 million in 2024, then increased by 0.9% to $156.6 million in 2025.
  • The last three reported values for Accumulated Depreciation & Amortization were $156.6 million (Q4 2025), $155.2 million (Q4 2024), and $144.9 million (Q4 2023) per Business Quant data.